Dr. Kim Kamdar is a Co-Founder and serves as Chairman at Seraphina Therapeutics. She also serves as Board Member, Chairperson of Nominating and Corporate Governance Committee and Member of Compensation Committee at Obalon Therapeutics. She serves as a Partner at Domain Associates. She serves as Board Member at Aspen Neuroscience. She also serves as Board Member at Singular Genomics. She is a Co-Founder of Truvian Sciences and also serves as its Board Member. She is also a Board Member of San Diego Venture Group and Neothetics. She joined Domain in 2005 and became a partner in 2011. With a background in small molecule drug discovery, she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine. Prior to Domain, she was a Kauffman Fellow with MPM Capital. Prior to joining MPM, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. She is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. Kim serves as an advisory board member of Eric Topol's NIH-supported Clinical and Translational Science Award for Scripps Medicine and of Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego's CONNECT Foundation.